Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-04-25

Clinical Trial Update: Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for avelumab plus BCG in non-muscle invasive bladder cancer (Phase 1/2) with completed status and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Avelumab (avelumab)
  • BCG (Bacillus Calmette-Guérin)

Snippet

Sponsor: University of Oklahoma | Conditions: Bladder Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-04-25